{"entity":{"id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","aka":[],"tldr":"A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of Daratumumab is a phase 3 interventional study registered as NCT05438043 by Janssen Research & Development, LLC, with 213 participants enrolled, started 2022-12-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05438043","url":"https://clinicaltrials.gov/study/NCT05438043"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["daratumumab","carfilzomib","dexamethasone","lenalidomide","pomalidomide"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05438043","phase":"3","setting":"A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study","sponsor":"Janssen Research & Development, LLC","enrolled":213,"outcomes":[]},"route":"/trials/nct05438043/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}